Welcome to the Journal of Lung Health and Diseases

Manuscript Guidelines

The journal has specific rules to formatting a manuscript that authors should adhere to before shipping their manuscript. These guidelines are primarily intended to make the submission of manuscript quick and easy.    Read More

click here

Ethics & Disclosures

Journal of Lung Health and Diseases is primarily based on values centered on loyalty, commitment, scientific accuracy, and ethics. It has adopted clear and rigorous ethical guidelines for best working practices.    Read More

What happens next to your Submission

Each article we publish benefits from hundreds of hours of work by Chief editors, Sectional editors, Reviewers, Manuscript editors, Proofreaders, Graphics and Web experts, who work to ensure that the manuscript meets our standards.    Read More

cover-image

Focus & Scope


Journal of Lung Health and Diseases is a special feature on Respiratory Diseases and Health. It provides valuable insight into the detection, diagnosis, prevention, and treatment of lung diseases both acute and chronic. It is dedicated to publication of original work in research, research methods, and program evaluation in the field of respiratory health. The Journal also regularly publishes editorials and commentaries and serves as a forum for health policy analysis. The mission of the Journal is to advance lung health research, policy, practice, and education.

This journal aims to raise lung health awareness of global public, and also provide a platform for pulmonologists to share and discuss their ideas which plays a key role in the development of enhanced diagnostic and treatment regimens further improving the quality of life in people suffering from pulmonary disorders.

Read more

e-Submission

Recent Articles


Vol 3-2 Summary

A summary of Evaluation of Asthma Control in Children Using Childhood-Asthma Control Test (CACT) and Asthma Therapy Assessment Questionnaire (ATAQ)

AR Somashekar*, KG Ramakrishnan

Department of Pediatrics, MS Ramaiah Medical College and Hospitals, Bengaluru, Karnataka, India

View / Download Pdf View Full Text
Vol 3-2 Review

Fluticasone Furoate: A Once Daily Preparation in Patients with Persistent Asthma

Paul A. Lilburn1*, Henry Ainge-Allen1, Paul S. Thomas1,2

1Department of Respiratory Medicine, Prince of Wales’ Hospital

2Prince of Wales’ Clinical School and Mechanisms of Disease and Translational Research, University of New South Wales, NSW, Faculty of Medicine, University of New South Wales, NSW, Australia

Asthma affects approximately 240 million people worldwide. It is characterised by an allergic pattern of smooth muscle constriction and airway inflammation, and if chronic, the inflammation can lead to structural changes and fixed airflow obstruction. Bronchodilators relieve the bronchoconstriction, while inhaled corticosteroids reduce the airway inflammation. This paper reviews fluticasone furoate (FF), a novel inhaled corticosteroid with 24-hour duration of action. It is a synthetic fluorinated corticosteroid with agonist activity at the glucocorticoid receptor (GRE). It is reported to have a fast association and slow dissociation from the GRE compared to other ICSs. FF has been found to have a greater lung retention time than all other ICS preparations which may contribute to the extended duration of anti-inflammatory action. FF has extensive first pass hepatic metabolism resulting in a low gastrointestinal bioavailability which is consistent with the findings for other ICS preparations. FF, however, will pass from the lung into the systemic circulation and therefore an adverse profile similar to all ICS is likely, but long term data are needed.

FF has demonstrated treatment efficacy for asthma between 100μg and 200μg alone, but in combination with the long-acting beta agonist, vilanterol (FF/VIL 200μg/50μg OD) there were further improvements in lung function relative to monotherapy. There is an increased risk of pneumonia identified in patients with airways disease in associated with ICS preparations and surveillance will be required to determine if this also applies to FF. Once daily therapy, such as FF, may improve compliance and could hopefully be translated into further improvements in asthma-related outcomes.

View / Download Pdf View Full Text
Vol 3-2 Commentary

Commentary: Novel Insight into the Genetic Basis of High Altitude Pulmonary Hypertension in Kyrgyz Highlanders

Tsering Stobdan1 and Gabriel G. Haddad1, 2, 3*

1Division of Respiratory Medicine, Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA

2Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA

3Rady Children's Hospital, San Diego, CA 92123, USA

View / Download Pdf View Full Text
Vol 3-2 Research Article

Complement Factor (C3) Level as Marker of Inflammation in Paediatric Asthma

AR Somashekar1*, KG Ramakrishnan1, Vanitha Gowda2

1Department of Pediatrics, M.S. Ramaiah Medical College and hospitals, Bangalore, India

2Department of Biochemistry, M.S. Ramaiah Medical College and hospitals, Bangalore, India

Aim: To assess the serum levels of a complement factors C3 in Indian asthmatic children and compare them with those of healthy controls in order to establish a relationship between the levels of these factors and asthma disease process.

Method: Serum c3 levels of 44 children with acute asthma and 44 controls of the age group of 6-16 years was determined and statistically compared. Lung function tests (FEV1%) was done and correlated with serum c3 levels using Pearson’s comparison coefficient.

Results: The mean serum c3 value of cases (138±32.99) is higher than the controls (112.82±14.6), with 32% cases showing higher than normal level of serum C3. Pearson’s correlation coefficient reveals negative correlation between FEV1% with serum C3 levels.

Conclusion: This study reveals that serum levels of complement c3 are statistically higher in subjects with asthma as compared to healthy subjects. Further, serum levels of c3 reflect the severity of the disease, with its levels being higher when disease is more severe.

View / Download Pdf View Full Text
Click here for more articles

Special Features to Authors

Editing Services

We offer editing services to help you prepare a submission-ready manuscript.
Learn more

Article Outreach

The journal works hard to maximize the impact of published research.
Learn more

Reprints

Journal of Lung Health and Diseases offers a professional quality Reprint Service that enables users to have reprints delivered to their door at an affordable value.
Learn more